Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV

The information in the brief version is excerpted directly from the full-text guidelines. The brief version is a compilation of the tables and boxed recommendations.

  •   Table of Contents

Download Guidelines

Appendix B: Panel Roster and Financial Disclosures

Syphilis

Last Updated: August 1, 2019; Last Reviewed: August 1, 2019

Syphilis
Member Financial Disclosure
Company Relationship
Bolan, Gail Centers for Disease Control and Prevention None N/A
Ghanem, Khalil Johns Hopkins University None N/A
Hollier, Lisa Baylor College of Medicine None N/A
Hook, Edward W. 
University of Alabama at Birmingham
National Institutes of Health Research Support
Sena, Arlene University of North Carolina Gilead Sciences Research Support
GlaxoSmithKline
Research Support
Hologic, Inc
Speaking Compensation, Advisory Board
Lupin Pharmaceuticals, Inc Research Support
UpToDate Royalties
Stoner, Brad Washington University School of Medicine None N/A
Workowski, Kim* Emory University Acuris Research Support
Gilead Sciences Advisory Board, Research Support
GlaxoSmithKline Advisory Board, Research Support
Janssen Pharmaceuticals Advisory Board

* Group lead

Note: Members were asked to disclose all relationships from 12 months prior to the updated date. The period of reporting was from August 1, 2018, through August 1, 2019.

Download Guidelines